This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merit Medical Gains 26.4% Year to Date: What's Driving the Stock?
by Zacks Equity Research
MMSI's shares gain on the back of strength in its Cardiovascular segment and a robust product portfolio.
SNN Stock Declines Despite the Launch of Its Patient-Matched Guides
by Zacks Equity Research
Smith & Nephew announces the launch of its TOTAL ANKLE Patient-Matched Guides to plan and perform total ankle replacement procedures.
iRhythm's Zio ECG System Gets Approval in Japan, Stock Falls
by Zacks Equity Research
IRTC's Zio ECG monitoring system gets approval in Japan, marking a significant step in revolutionizing arrhythmia diagnostics with AI-powered technology.
Avanos Medical Stock May Gain From Brand Partnership With NFL
by Zacks Equity Research
AVNS' GAME READY announces a paid partnership with NFL defensive end and San Francisco 49ers star, Nick Bosa.
SYK Stocks Gains Following Expansion of Foot & Ankle Portfolio
by Zacks Equity Research
Stryker unveils two new products, enhancing precision and outcomes in foot and ankle surgeries.
Factors Driving Veeva Stock More Than 20% in Three Months
by Zacks Equity Research
Robust quarterly results on the back of new partnerships and rising subscription revenues are driving VEEV's shares.
Why Brookdale May Not Be a Safe Bet Despite 34-Month Occupancy Growth
by Zacks Equity Research
Rising operating costs due to inflationary challenges in the senior living industry and higher estimated insurance expenses are likely to keep BKD's margins under pressure.
PacBio Stock Drops After Singapore Collaboration for HiFi Sequencing
by Zacks Equity Research
PACB's HiFi sequencing powers the HiFi Consortium's global effort to enhance the diagnosis and treatment of subfertility and recurrent pregnancy loss.
Labcorp Stock Gains From Market Expansion Efforts Amid Macro Woes
by Zacks Equity Research
LH is well-placed for long-term success in Cell & Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business.
Solventum Shares May Gain on the Launch of Its New V.A.C Therapy
by Zacks Equity Research
SOLV announces the launch of its V.A.C. Peel and Place Dressing for providing efficient and effective care in case of negative pressure wound therapy.
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
by Zacks Equity Research
PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.
PacBio's Stock Up on Munster Deal for Male Infertility Research
by Zacks Equity Research
PACB collaborates with the University Hospital of Munster, using Revio HiFi sequencing to advance research on male infertility and rare diseases in Germany and globally.
Paragon 28 Stock Gains From the Latest Launch of Its Right-Angle Drill
by Zacks Equity Research
FNA launched the Right-Angle Drill to enhance the APEX 3D Total Ankle Replacement System. The drill is designed to improve tibia preparation.
Glaukos Stocks Rides on Strong Product Demand Amid Competition
by Zacks Equity Research
GKOS continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.
MASI Stock Down Despite New SafetyNet Deal for Neonatal Care
by Zacks Equity Research
The latest adoption of Masimo's SafetyNet is likely to improve the care provided to premature newborns and facilitate their early discharge from the hospital.
iRhythm Stock Gains Following Favorable Zio Monitor Study Data
by Zacks Equity Research
IRTC announces initial findings demonstrating the superior real-world performance of the next-generation Zio LTCM Monitor at the HRX 2024 meeting.
Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device
by Zacks Equity Research
FEMY gains after FDA clearance for FemChec, a fallopian tube diagnostic tool designed for safe, in-office use, enhancing non-surgical birth control procedures.
Here's Why You Should Retain PDCO Stock in Your Portfolio for Now
by Zacks Equity Research
Investors remain optimistic about Patterson Companies on the back of its broad product line.
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
by Zacks Equity Research
GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.
PBH Stock Might Get a Boost From Focused Brand-Building Efforts
by Zacks Equity Research
Prestige Consumer puts emphasis on brand building and product innovation in niche consumer healthcare categories to improve the lives of its consumers.
Fresenius Medical Care Stock Rises on NxStage VersiHD Launch
by Zacks Equity Research
FMS introduces NxStage VersiHD with GuideMe Software to simplify home dialysis and grow its patient base in the United States.
VEEV Stock Up Following the Release of New Features of Veeva Site Connect
by Zacks Equity Research
Veeva Systems' Site Connect is likely to aid the sponsors in reducing trial time and expense.
iRhythm Stock May Gain on Its Latest Deal With BioIntelliSense
by Zacks Equity Research
IRTC announces an exclusive license agreement with BioIntelliSense to develop and commercialize certain patented technology assets within AMC.
COO Stock Up 0.4% Following the Launch of New Inserter for Paragard IUD
by Zacks Equity Research
Cooper Companies' latest launch is likely to simplify the insertion process of Paragard IUD, thus making it a more accessible contraceptive choice.
DENTSPLY SIRONA Stock May Gain on the Launch of Primescan 2
by Zacks Equity Research
XRAY introduces its new-generation intraoral scanner, Primescan 2, to provide effective and efficient care and comfort to patients.